Trial: 201904154

A Phase 2, Open-Label Study of Encorafenib + Binimetinib in Patients with BRAFV600E-mutant Non-small Cell Lung Cancer

Phase

II (Cancer Control)

Principal Investigator

Morgensztern, Daniel

Disease Site

Lung; Lung Cancer – Non-small Cell

Learn more about this study at: clinicaltrials.gov